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enough for the field to maintain current
clone IDs (thus allowing ‘‘self-renewal’’),
while giving us time to adopt a differenti-
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DOI 10.1016/j.stem.2011.05.011Based on its history as a repository of
biomaterialdiversity, theATCCrecognizes
the importance of a naming convention
that is both clearly descriptive and consis-
tently applied. We therefore agree with
and support the objective of the authors
of ‘‘A Call for Standardized Naming and
Reporting of Human ESC and iPSC Lines’’
(Luong et al., 2011). We have some addi-
tional suggestions to clarify and broaden
the naming convention.
Pluripotent stem cell lines of various
sources display significant differences in
methylation signature and/or differentia-
tion ability (Hanna et al., 2010; Bock
et al., 2011; Lister et al., 2011; Burridge
et al., 2011; Kattman et al., 2011). As
such, there is an ever-growing call for
standardization to define what ‘‘pluripo-
tent cell’’ means as a strict cell biology
definition. This definition will be more
accurately determined if we include the
character of pluripotent cells of all types.
Therefore, the naming convention should
include designations for embryonal carci-
noma cells, parthenogenic stem cells, and
epiblast stem cells in addition to the i or e
used to designate the induced or embry-
onic origin of pluripotency.
In addition, we caution against use of
the word ‘‘disease’’ in naming pluripotent
cells as this breeds ambiguity. Many
iPSCs have been derived from neonatal
foreskin fibroblasts, and thus serve as
nondiseased controls. Because of ano-
nymization of donors, it is unknown
whether they may display disease later inlife or have children who grow up to
develop a disease where the donor is
a carrier or where disease penetrance
is variable. For many multifactorial dis-
orders, disease etiology is complex;
diseases such as diabetes or cardiovas-
cular disease have divergent genetic
origins. This susceptibility to disease
may not be manifest in the iPSCs or in
any of the differentiated cell types derived
from them (Soldner et al., 2009). There-
fore, the terms ‘‘healthy’’ and ‘‘diseased’’
do not have clear meaning in the context
of pluripotent cells. After all, no pluripotent
cell donor is normal or healthy, but some-
where within a spectrum of genetic diver-
sity and susceptibility to disease. We
suggest that the specification of disease
should be replaced by a descriptor of the
known genetic mutation or lack of known
genetic mutations. Medical history of the
donor is too long to be included in the
name, and should be found in any accom-
panying cell description.
A last but practical point to be consid-
ered is that the name should be short
enough to fit clearly on the label of
a 1.5 ml cryoampule when written with an
indelible marker by a gloved hand. That
is a tall order, butwesuggest that thechar-
acter number should not be more than 10.
We would propose that the following be
key elements of the name: lab origin (two
letter code, similar to the system used to
name candidate drugs); source organ
(two letters such as ec for embryonal
carcinoma); sex (X or Y); presence orabsence of permanent genetic modifica-
tion (i for insertions, n for no insertions);
and a unique four-number code that
would be linked to a known genetic iden-
tity or subclone from a parent line.
As a member of the stem cell research
community, the ATCC expects that
pluripotent cells will continue to have
a transformative effect on the study of
human disease, the evaluation of drugs,
and the replacement of damaged tissues.
The ATCC feels that the standardization
of naming, cell definition, and cell char-
acter are all essential measures to help
realize that potential. Recognizing the
positive impact a nonprofit organization
that specializes in preserving biomaterial
diversity can have in this area, the ATCC
has established a repository exclusive to
pluripotent cells. In accordance with the
ATCC mission, this repository was de-
signed with the goal of enabling research
by providing cells that are licensed for
research use.
The cells in the ATCC repository will
meet the criteria for pluripotency estab-
lished through dialog with experts in the
field. Quality, consistency, and reliability
will be assured through the application
of rigorous QC specifications. In conjunc-
tion with this effort, the ATCC is devoting
resources to create an online database
to store and organize descriptive and
experimental data related to pluripotent
cells. The ATCCwill seek the participation
of stem cell researchers in the creation of
these tools in order to harmonize theell 8, June 3, 2011 ª2011 Elsevier Inc. 607
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Letterspractices that will ultimately lead to more
transparent and accessible sharing of
pluripotent cells.REFERENCES
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